Advertisement
Screener

ORAGENICS, INC. (OGEN) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

0.9 / 5 stars · 10/53 Roast Me

ORAGENICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

ORAGENICS, INC. (OGEN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $105.90 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-16

  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $19.57.
  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.53.
  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $105.90, a 669.62% increase from fiscal 2024.
  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $13.76, a 74.01% decline from fiscal 2023.
  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $52.94, a 10.34% increase from fiscal 2022.
  • ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $47.98, a 3898.33% increase from fiscal 2021.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed
2025-12-31$105.90
10-K · filed 2026-03-16
2024-12-31$13.76
10-K · filed 2025-03-14
2024-09-30$11.52
10-Q · filed 2024-11-13
2024-06-30$11.52
10-Q · filed 2024-08-09
2024-03-31$19.57
10-Q · filed 2024-05-15
2023-12-31$52.94
10-K · filed 2024-03-29
2022-12-31$47.98
10-K · filed 2023-04-17
2022-09-30$0.94
10-Q/A · filed 2023-04-14
2022-06-30$0.94
10-Q/A · filed 2023-04-14
2022-03-31$1.53
10-Q/A · filed 2023-04-14
2021-12-31$1.20
10-K/A · filed 2022-07-29
2021-09-30$1.65
10-Q · filed 2021-11-15
2021-06-30$1.24
10-Q · filed 2021-08-16
2020-12-31$100.00
10-K · filed 2021-03-01
2020-09-30$100.00
10-Q · filed 2020-11-10
2020-06-30$100.00
10-Q · filed 2020-08-14
2019-12-31$54.00
10-K · filed 2020-03-04
2018-12-31$104.00
10-K · filed 2019-03-29
2017-12-31$16.50
10-K · filed 2019-03-29
2016-12-31$24.00
10-K · filed 2018-02-16
$2.40
10-K · filed 2017-02-27
2015-12-31$5.71
10-K · filed 2017-02-27
2014-12-31$2.93
10-K · filed 2016-03-30
2013-12-31$2.19
10-K · filed 2015-02-27
2012-12-31$3.42
10-K · filed 2014-02-28
2011-12-31$6.50
10-K · filed 2013-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02